Interstitial lung disease sequelae of COVID-19
Research type
Research Study
Full title
Interstitial lung disease sequelae of COVID-19
IRAS ID
302642
Contact name
Onn Min Kon
Contact email
Sponsor organisation
Imperial College Healthcare NHS Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
COVID-19 infection may damage the lungs in different ways and has been seen to result in scarring of the lungs, known as interstitial lung disease (ILD). This can result in significant symptoms, including breathlessness, which may have a significant impact on a patient's quality of life. There is currently limited evidence regarding which patients who have had COVID-19 are at risk of developing ILD, how long their symptoms may last and what their blood tests, lung function test results and radiological scans may show. Understanding correlation between these factors and outcome at 12-months post infection will enable clinicians to tailor care and be able to explain to patients what to expect should they develop fibrotic changes on their scans. Understanding this will also have important implications for the way in which this group of patients are cared for in healthcare institutions both in the short-term and long-term. This study aims to address this research gap and area of important unmet clinical need. By developing an understanding of the clinical characteristics of patients who develop ILD after COVID-19, we aim to describe the clinical findings in these patients and identify how they should be optimally investigated and managed in an outpatient clinic setting.
REC name
South West - Cornwall & Plymouth Research Ethics Committee
REC reference
21/SW/0138
Date of REC Opinion
1 Nov 2021
REC opinion
Favourable Opinion